LIVE POLIO IRUS VACCINES

More documents

Recommendations

Info

I TTmTIIITITIT?~~~~~~~~~~T~~~TTTT~~~~m~~T~~irmmT lol FOURTH SESSION TUESDAY, 7 JUNE 1960, 2:00 P.M. Chairman DR. JAMES H. S. GEAR Director, South African Institute for Medical Research Johannesburg, South Africa TOPIC II. SAFETY. (B) FIELD EVIDENCE OF SAFETY (continuation) (2) SPREAD OF V<strong>IRUS</strong> IN THE COMMUNITY Presentation of Papers by: Dr. Sven Gard Dr. Masami Kitaoka (DISCUSSION) (3) SAFETY IN PREGNANCY AND FOR THE NEWBORN Dr. Konald A. Prem TOPIC III. EFFICACY. (A) LABORATORY EVIDENCE (1) ANTIBODY RESPONSE (a) Methodology Presentation of Papers by: Dr. V. Vonka Dr. Marina K. Voroshilova (DISCUSSION) (b) Influence of Age Dr. Natan Goldblum Dr. Joseph S. Pagano 185
Page 1 and 2:
LIVE POLIO IRUS VACCINES Papers Pre
Page 3 and 4:
SECOND INTERNATIONAL CONFERENCE ON
Page 5:
Preface The accumulation of informa
Page 8 and 9:
Page Discussion .......... .......
Page 10 and 11:
Page 6. Vaccination of Full-Term In
Page 12 and 13:
Page 23. Vaccination against Poliom
Page 14 and 15:
Dr. Ghislain COURTOIS Director, Pri
Page 16 and 17:
Dr. Edith PETTE Institute for the R
Page 18:
imimmmmmñimmimmm-ñmñmñrmimmimmm
Page 21 and 22:
4 Introductory Remarks 4 Introducto
Page 23 and 24:
6 General Considerations immunity a
Page 25 and 26:
8 General Considerations from accep
Page 27 and 28:
10 General Considerations 10 Genera
Page 29 and 30:
_nTlmmlllllTlllllllnT/I1T~lllmlimll
Page 31 and 32:
14 Safety-Laboratory Evidence of At
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
- 26 Safety-Laboratory Evidence of
Page 45 and 46:
DISCUSSION CHAIRMAN ANDERSON: There
Page 47 and 48:
30 Discussion CHAIRMAN ANDERSON: Th
Page 49 and 50:
32 TABLE 1. Safety-Laboratory Evide
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
40 Discussion Of the 22 monkeys inf
Page 59 and 60:
Page 61 and 62:
DISCUSSION CHAIRMAN ANDERSON: Thank
Page 63 and 64:
46 Discussion a paralytic case. Thi
Page 65 and 66:
48 Discussion + - + + I + - I + + 1
Page 67 and 68:
50 Discussion sages of neurovirulen
Page 70 and 71:
UUYaYLlrmUIIIIIIYYIi1IYllllliTI11II
Page 72 and 73:
Application of Genetic Markers to D
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Discussion 67 TABLE 1. INCIDENCE OF
Page 86 and 87:
Experimental Studies on Animals wit
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
6. DETECTION OF A "NON-DETECTABLE"
Page 98 and 99:
Detection of a "Non-Detectable" Sim
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Discussion 87 Dr. Koprowski's state
Page 106 and 107:
Discussion 89 recognize its effects
Page 108 and 109:
Laboratory Investigations of Attenu
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Discussion 99 In the case of Table
Page 118 and 119:
8. BEHAVIOR OF COLD MUTANTS OF POLI
Page 120 and 121:
Behavior of Cold Mutants of Poliovi
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
DISCUSSION CHAIRMAN BURNET: Thank y
Page 128:
IULUUmmiillaYIIiiiiIllnllTrTnTnTm T
Page 131 and 132:
114 Safety-Field Evidence of Safety
Page 133 and 134:
Page 135 and 136:
118 S afety-Field Evidence of S af
Page 137 and 138:
Page 139 and 140:
122 Discussion 122 Discussion~~~~~~
Page 141 and 142:
10. LABORATORY INVESTIGATIONS OF TH
Page 143 and 144:
126 VIRUS 1 MAhONEY Safety-Field Ev
Page 145 and 146:
128 Safety-Field Evidence óf Safet
Page 147 and 148:
Page 149 and 150:
DISCUSSION CHAIRMAN ZHDANOV: This p
Page 151 and 152: 11. EPIDEMIOLOGICAL AND VIROLOGICAL
Page 153 and 154: 136 Safety-Field Evidence of Safety
Page 161 and 162: 12. SPREAD OF A VACCINE STRAIN OF P
Page 165 and 166: 148 Saf ety-Field Evidence of Saf e
Page 169 and 170: 152 Saf ety-Field Evidence of Safet
Page 173 and 174: DISCUSSION CHAIRMAN ZHDANOV: The pa
Page 175 and 176: 158 Discussion 158 Díscussion~~~~~
Page 177 and 178: 160 Discussion specimens. We were u
Page 185 and 186: . . . 168 Safety-Field Evidence of
Page 191 and 192: 14. THE CAPACITY OF LIVE ATTENUATED
Page 193 and 194: 176 Saf ety-Field Evidence of Saf e
Page 195 and 196: ... ____ v __ _"_ _. ___.__ __ .,_.
Page 201: 184 Safety-Field Evidence of Safety
Page 207 and 208: 190 Safety-F'ield Evidence of Safet
Page 215 and 216: vaccine combined in a mixture conta
Page 219 and 220: DISCUSSION CHAIRMAN GEAR: Thank you
Page 221 and 222: . _ 204 Discussion I__ _ 1 CC w 4CC
Page 223 and 224: 206 206 Discussion Discussion We kn
Page 233 and 234: 216 216 Safety-Field Evidence of Sa
Page 241 and 242: 224 Saf etv-Field Evidence of Saf e
Page 243 and 244: The authors wish to express their a
Page 245 and 246: IIIIIII1I1)1III1II111111:l lrmillll
Page 247 and 248: - 230 Efficacy-Laboratory Evidence
Page 249 and 250: 232 Efficacv-Laboratory Evidence l2
Page 251 and 252: 234 Efficacy-Laboratory Evidence 40
Page 253 and 254:
236 Efflcacy-Laboratory Evidence 23
Page 255 and 256:
Page 257 and 258:
2. VIROLOGIC AND SEROLOGIC INVESTIG
Page 259 and 260:
242 Efficacy-Laboratory Evidence ca
Page 261 and 262:
244 Efficacy-Laboratory Evidence Z
Page 263 and 264:
246 Efficacy-Laboratory Evidence TA
Page 265 and 266:
Page 267 and 268:
250 Efficacy-Laboratory Evidence LO
Page 269 and 270:
Page 271 and 272:
254 TABLE 21. Efficacy-Laboratory E
Page 273 and 274:
256 Efficacy-Laboratory Evidence QC
Page 275 and 276:
258 Efficacy-Laboratory Evidence Is
Page 277 and 278:
260 Efficacy-Laboratory Evidence o
Page 279 and 280:
Page 281 and 282:
264 Effcaey-Laboratory Evidence 264
Page 283 and 284:
DISCUSSION CHAIRMAN GEAR: The last
Page 285 and 286:
268 Discussion " I10,00 1-- , 2,000
Page 287 and 288:
3. VIROLOGICAL FINDINGS AND ANTIBOD
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
276 Efficacy-Laboratory Evidence 27
Page 295 and 296:
278 Efficacy-Laboratory Evidence sq
Page 297 and 298:
280 Efficacy-Laboratory Evidence Po
Page 299 and 300:
282 Efficacy-Laboratory Evidence to
Page 302:
_____~~~~~~~~~~~~~~~~~~~~~~ FIFTH S
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
6. VACCINATION OF FULL-TERM INFANTS
Page 313 and 314:
296 296 Efficacy-Laboratory Evidenc
Page 315 and 316:
Page 317 and 318:
300 Efflcacy-Laboratory Evidence TA
Page 319 and 320:
7. THE RESPONSE OF NEWBORN INFANTS
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
8. PRELIMINARY REPORT ON THE SUSCEP
Page 327 and 328:
310 310 Efficaey-Laboratory Evidenc
Page 329 and 330:
312 Efficacy-Laboratory Evidence ch
Page 331 and 332:
314 314 Efficacy-Laboratory Evidenc
Page 333 and 334:
Page 335 and 336:
318 TABLE 3. Efficacy-Laboratory Ev
Page 337 and 338:
320 Efficacy-Laboratory Evidence (u
Page 339 and 340:
DISCUSSION CHAIRMAN HILLEBOE: Befor
Page 341 and 342:
324 Discussion INFLUENCES OF ANTIBO
Page 343 and 344:
326 Discussion 326 Discussion Would
Page 345 and 346:
328 Discussion if we give the Black
Page 347 and 348:
10. RECENT EXPERIENCE WITH THE LEDE
Page 349 and 350:
332 Efficacy-Laboratory Evidence O/
Page 351 and 352:
Page 353 and 354:
336 Efficacy-Laboratory Evidence pr
Page 355 and 356:
338 Efficacy--Laboratory Evidence G
Page 357 and 358:
340 Efficacy-Laboratory Evidence CD
Page 359 and 360:
Page 361 and 362:
344 Efficacy-Laboratory Evidence ti
Page 363 and 364:
i . ;; ,---- , , _ ·, ,,, ,, 346 E
Page 365 and 366:
348 Efficacy-Laboratory Evidence ta
Page 367 and 368:
Page 369 and 370:
352 Efficacy-Laboratory Evidence mo
Page 372:
ITnTTITTTIIrmrTTTmTTmTmm - niiii ii
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
368 Efflcacy-Laboratory Evídence 3
Page 387 and 388:
370 Efficacy-Laboratory Evidence RE
Page 389 and 390:
372 372 Discussion Discussion~~~~~~
Page 391 and 392:
374 Discussion 374 Discussion~~~~~
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
384 Effieacy-Laboratory Evidence 38
Page 403 and 404:
15. USE OF SABIN'S LIVE POLIOVIRUS
Page 405 and 406:
388 Efficacy-Laboratory Evidence o
Page 407 and 408:
Page 409 and 410:
_ 392 Efficacy-Laboratory Evidence
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
402 Efficacy-Laboratory Evidence z
Page 421 and 422:
404 Efficacy-Laboratory Evidence )
Page 423 and 424:
406 Efficacy-Laboratory Evidence c
Page 425 and 426:
408 Efficacy-Laboratory Evidence l)
Page 427 and 428:
DISCUSSION CHAIRMAN LÉPINE: The pa
Page 429 and 430:
412 Discussion tion. I do not see h
Page 431 and 432:
414 Efficacy-Field Evidence ference
Page 433 and 434:
416 Effcacy-Field Evidence TABLE 3.
Page 435 and 436:
418 Efficacy-Field Evidence DAYS OF
Page 437 and 438:
preparation. Large-scale field tria
Page 439 and 440:
422 Efficacy-Field Evidence taneous
Page 441 and 442:
424 Efficacy-Field Evidence TABLE 1
Page 443 and 444:
426 Efficacy-Field Evidence 2048 ,a
Page 445 and 446:
428 Efficacy-Field Evidence 60o S0
Page 447 and 448:
Page 449 and 450:
432 Discussion tioned already in th
Page 452 and 453:
lilllmlllllll'll1lllllilrrmllllllll
Page 454 and 455:
Large-Scale Field Trial with Oral C
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
18. PRELIMINARY REPORT OF EPIDEMIOL
Page 464 and 465:
Epidemiological Surveillance in Mas
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
DISCUSSION CHAIRMAN RHODES: These t
Page 476 and 477:
Discussion 459 -~~~~Dsuso 5 We did
Page 478 and 479:
Discussion 461 logical anomalies of
Page 480 and 481:
Discussion 463 The majority of chil
Page 482:
case of poliomyelitis, if it was po
Page 485 and 486:
Page 487 and 488:
470 Efficacy-Field Evidence 470 Eff
Page 489 and 490:
Page 491 and 492:
20. LIVE VIRUS VACCINE STUDIES IN S
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
DISCUSSION CHAIRMAN RHODES: These t
Page 499 and 500:
21. MATERIAL ON THE IMMUNOLOGICAL A
Page 501 and 502:
484 Efficacy-Field Evidence 484 Efi
Page 503 and 504:
486 Efficacy-Field Evidence 486 iEf
Page 505 and 506:
488 Efficacy-Field Evidence - TABLE
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
494 Efficaey-Field Evidence TABLE 9
Page 513 and 514:
496 Efficaey-Field Evidence TABLE 1
Page 515 and 516:
498 Efficacy-Field Evidence Qo - Co
Page 517 and 518:
500 Etfficacy-Field Evidence 500 Ef
Page 520:
lmllliiimlll1llrrmmIiiiiiiiiiiiiii,
Page 523 and 524:
506 Discussi on hausted the morbidi
Page 525 and 526:
Page 527 and 528:
510 Efficacy-Field Evidence b 'r3 `
Page 529 and 530:
512 ol o c,- 4 3- 0 7 Efficacy-Fiel
Page 531 and 532:
514 Efficacy-Field Evidence b, U *
Page 533 and 534:
516 Efficacy-Field Evidence o e 0 1
Page 535 and 536:
518 Efficacy-Field Evidence in the
Page 537 and 538:
520 Efficacy-Field Evidence thing w
Page 539 and 540:
23. VACCINATION AGAINST POLIOMYELIT
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
528 Efficacy-Field Evidence MAP 2.
Page 547 and 548:
Page 549 and 550:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 551 and 552:
534 Efficacy-Field Evidence a still
Page 553 and 554:
536 Efficacy-Field Evidence frigera
Page 555 and 556:
538 TABLE 3. Efficacy-Field Evidenc
Page 557 and 558:
540 Efficacy-Field Evidence sented
Page 559 and 560:
Page 561 and 562:
544 Efficacy-Field Evidence Antibod
Page 563 and 564:
546 Efficacy-Field Evidence 250t 20
Page 565 and 566:
Page 567 and 568:
550 Efficacy-Field Evidence FIGURE
Page 569 and 570:
552 Efficacy-Field Evidence u o o
Page 571 and 572:
-Y 554 Efficacy-Field Evidence TABL
Page 573 and 574:
556 -- Efficacy-Field Evidence 0
Page 575 and 576:
c 558 Efficacy-Field Evidence o z o
Page 577 and 578:
560 Efficacy-Field Evidence Clayton
Page 579 and 580:
562 Efficacy-Field Evidence 2. Triv
Page 581 and 582:
564 Efficacy-Field Evidence and by
Page 583 and 584:
566 Efficacy-Field Evidence establi
Page 585 and 586:
568 Efficacy-Field Evidence Costa R
Page 587 and 588:
570 Efficacy-Fi eld Evidence Two su
Page 589 and 590:
572 Efficacy-Field Evidence o0 u p
Page 591 and 592:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 593 and 594:
27. LARGE-SCALE PRACTICAL TRIALS AN
Page 595 and 596:
578 Efficacy-Field Evidence some of
Page 597 and 598:
580 Efficacy-Field Evidence vaccine
Page 599 and 600:
582 Efficacy-Field Evidence more th
Page 601 and 602:
584 Efficacy-Field Evidence medical
Page 603 and 604:
586 Efficacy-Field Evidence immuniz
Page 605 and 606:
588 Efficacy-Field Evidence nationa
Page 608 and 609:
DISCUSSION CHAIRMAN VARGAS-MÉNDEZ:
Page 610 and 611:
Discussion 593 -~~~~~isuso 9 a stoo
Page 612 and 613:
Discussion 595 If the chain of tran
Page 614 and 615:
dence of immunization within a few
Page 616 and 617:
Discussion 599 the people in a few
Page 618 and 619:
Summary of the Conference 601 prese
Page 620:
The occurrence of poliomyelitis in
Page 624 and 625:
INDEX Abad Gómez, Héctor, 369 Abo
Page 626 and 627:
Index 609 Attack rates-continued hi
Page 628 and 629:
Index 611 Chromatography purificati
Page 630 and 631:
Index 613 Dosage-continued statisti
Page 632 and 633:
Index 615 Field trials-continued Le
Page 634 and 635:
Index 617 Human tissue-culture syst
Page 636 and 637:
Index 619 Intestinal tract-continue
Page 638 and 639:
Index 621 Markush, R. E., paper 435
Page 640 and 641:
Index 623 Newborns-continued degree
Page 642 and 643:
Index 625 Poliomyelitis, paralytic-
Page 644 and 645:
Index 627 Reversion dangers of, 485
Page 646 and 647:
Index 629 Spread-continued in the c
Page 648 and 649:
Index 631 Vaccination-continued rep
Page 650 and 651:
Index 633 Vaccine, Attenuated, Triv
show all

LIVE POLIO IRUS VACCINES

Create successful ePaper yourself

Delete template?

Save as template?